WAS
MCID: WSK001
MIFTS: 76

Wiskott-Aldrich Syndrome (WAS)

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Wiskott-Aldrich Syndrome

MalaCards integrated aliases for Wiskott-Aldrich Syndrome:

Name: Wiskott-Aldrich Syndrome 58 39 12 77 26 60 76 38 30 13 13 56 6 45 15 41 74
Eczema-Thrombocytopenia-Immunodeficiency Syndrome 58 26 60 76
Immunodeficiency 2 58 54 26 76
Was 58 54 60 76
Aldrich Syndrome 58 54 76
Imd2 58 26 76
Wiskott-Aldrich Syndrome 1 58 76
Wiskott Syndrome 12 26
Was1 58 76
Eczema Thrombocytopenia Immunodeficiency Syndrome 54
Wiskott-Aldrich Syndrome 1; Was1 58
Immunodeficiency 2; Imd2 58
Wiskott Aldrich Syndrome 54
Imd 2 54

Characteristics:

Orphanet epidemiological data:

60
wiskott-aldrich syndrome
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable,X-linked recessive; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Infancy,Neonatal; Age of death: any age;

OMIM:

58
Inheritance:
x-linked recessive


HPO:

33
wiskott-aldrich syndrome:
Inheritance x-linked recessive inheritance


Classifications:



Summaries for Wiskott-Aldrich Syndrome

NIH Rare Diseases : 54 Wiskott Aldrich syndrome (WAS) is a disease with immunological deficiency and reduced ability to form blood clots. Signs and symptoms include easy bruising or bleeding due to a decrease in the number and size of platelets; susceptibility to infections and to immune and inflammatory disorders; and an increased risk for some cancers (such as lymphoma).  Also, a skin condition known as eczema is common in  people with WAS. Wiskott Aldrich syndrome  is caused by mutations in the WAS gene and is inherited in an X-linked manner. It primarily affects males. Treatment may depend on severity and symptoms in each person, but hematopoietic cell transplantation is the only known cure.  Hematopoietic cells are the blood-forming stem cells that can be found mainly in the sponge-like material found inside bones (bone marrow), but also in the bloodstream (peripheral blood stem cells (PBSCs),  and in the umbilical cord.Prognosis have improved over time due to better management of the disease. People who have a successful and uncomplicated hematopoeitic cell transplantation, usually have normal immune function and, normal survival. Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked neutropenia (XLN) are known as �??WAS-related disorders�?� because these diseases are all caused by mutations in the WAS gene, and have overlapping symptoms ranging from severe to mild (Wiskott-Aldrich syndrome is the most severe).  The WAS gene mutations result in deficiency of the Wiskott-Aldrich syndrome protein (WASP). The more deficient the WASP, the more severe the disease.

MalaCards based summary : Wiskott-Aldrich Syndrome, also known as eczema-thrombocytopenia-immunodeficiency syndrome, is related to wiskott-aldrich syndrome 2 and wiskott-aldrich syndrome, autosomal dominant form, and has symptoms including diarrhea and petechiae of skin. An important gene associated with Wiskott-Aldrich Syndrome is WAS (WASP Actin Nucleation Promoting Factor), and among its related pathways/superpathways are Endocytosis and Regulation of actin cytoskeleton. The drugs Dexmedetomidine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and skin, and related phenotypes are chronic otitis media and recurrent respiratory infections

Disease Ontology : 12 A X-linked recessive disease that is characterized by abnormal immune system function and a reduced ability to form blood clots resulting from a decrease in the number and size of blood cell fragments involved in clotting (microthrombocytopenia).

Genetics Home Reference : 26 Wiskott-Aldrich syndrome is characterized by abnormal immune system function (immune deficiency) and a reduced ability to form blood clots. This condition primarily affects males.

OMIM : 58 Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections (Lemahieu et al., 1999). (301000)

UniProtKB/Swiss-Prot : 76 Wiskott-Aldrich syndrome: An X-linked recessive immunodeficiency characterized by eczema, thrombocytopenia, recurrent infections, and bloody diarrhea. Death usually occurs before age 10.

Wikipedia : 77 Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema,... more...

Related Diseases for Wiskott-Aldrich Syndrome

Diseases in the Wiskott-Aldrich Syndrome family:

Wiskott-Aldrich Syndrome, Autosomal Dominant Form Wiskott-Aldrich Syndrome 2

Diseases related to Wiskott-Aldrich Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 wiskott-aldrich syndrome 2 12.8
2 wiskott-aldrich syndrome, autosomal dominant form 12.5
3 ectodermal dysplasia and immunodeficiency 2 12.0
4 storage pool platelet disease 11.5
5 specific antibody deficiency 11.5
6 immunodeficiency, common variable, 2 11.4
7 amegakaryocytic thrombocytopenia, congenital 11.1
8 thrombocytopenia 11.0
9 thrombocytopenia 1 10.9
10 lymphoma 10.8
11 hematopoietic stem cell transplantation 10.7
12 purpura 10.6
13 herpes simplex 10.6
14 colitis 10.5
15 glomerulonephritis 10.5
16 sarcoma 10.5
17 dermatitis 10.5
18 vasculitis 10.5
19 lymphosarcoma 10.5
20 cytomegalovirus infection 10.5
21 dermatitis, atopic 10.4
22 hyperostosis 10.4
23 iga glomerulonephritis 10.4
24 aortic aneurysm 10.4
25 progressive multifocal leukoencephalopathy 10.4
26 hepatocellular carcinoma 10.3
27 ovarian cancer 10.3
28 lymphoma, hodgkin, classic 10.3
29 reticulum cell sarcoma 10.3
30 lymphoma, non-hodgkin, familial 10.3
31 aortic aneurysm, familial thoracic 1 10.3
32 juvenile myelomonocytic leukemia 10.3
33 b-cell lymphomas 10.3
34 hepatitis 10.3
35 hepatitis b 10.3
36 leukemia 10.3
37 lymphomatoid granulomatosis 10.3
38 neutropenia 10.3
39 thrombotic thrombocytopenic purpura 10.3
40 sclerosing cholangitis 10.3
41 pneumonia 10.3
42 thyroiditis 10.3
43 cholangitis 10.3
44 alzheimer disease 10.2
45 burkitt lymphoma 10.2
46 caffey disease 10.2
47 breast cancer 10.2
48 renal cell carcinoma, nonpapillary 10.2
49 intussusception 10.2
50 kaposi sarcoma 10.2

Graphical network of the top 20 diseases related to Wiskott-Aldrich Syndrome:



Diseases related to Wiskott-Aldrich Syndrome

Symptoms & Phenotypes for Wiskott-Aldrich Syndrome

Human phenotypes related to Wiskott-Aldrich Syndrome:

60 33 (show top 50) (show all 74)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chronic otitis media 60 33 hallmark (90%) Very frequent (99-80%) HP:0000389
2 recurrent respiratory infections 60 33 hallmark (90%) Very frequent (99-80%) HP:0002205
3 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
4 immunodeficiency 60 33 hallmark (90%) Very frequent (99-80%) HP:0002721
5 sinusitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000246
6 thrombocytopenia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001873
7 spontaneous hematomas 60 33 hallmark (90%) Very frequent (99-80%) HP:0007420
8 chronic obstructive pulmonary disease 60 33 hallmark (90%) Very frequent (99-80%) HP:0006510
9 lymphopenia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001888
10 chronic diarrhea 60 33 hallmark (90%) Very frequent (99-80%) HP:0002028
11 bruising susceptibility 60 33 hallmark (90%) Very frequent (99-80%) HP:0000978
12 prolonged bleeding time 60 33 hallmark (90%) Very frequent (99-80%) HP:0003010
13 abnormal platelet morphology 60 33 hallmark (90%) Very frequent (99-80%) HP:0011875
14 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
15 dyspnea 60 33 frequent (33%) Frequent (79-30%) HP:0002094
16 hemolytic anemia 60 33 frequent (33%) Frequent (79-30%) HP:0001878
17 specific learning disability 60 33 frequent (33%) Frequent (79-30%) HP:0001328
18 autoimmunity 60 33 frequent (33%) Frequent (79-30%) HP:0002960
19 inflammation of the large intestine 60 33 frequent (33%) Frequent (79-30%) HP:0002037
20 microcytic anemia 60 33 frequent (33%) Frequent (79-30%) HP:0001935
21 petechiae 60 33 frequent (33%) Frequent (79-30%) HP:0000967
22 hematemesis 60 33 frequent (33%) Frequent (79-30%) HP:0002248
23 hematochezia 60 33 frequent (33%) Frequent (79-30%) HP:0002573
24 abnormal eosinophil morphology 33 frequent (33%) HP:0001879
25 sudden cardiac death 60 33 occasional (7.5%) Occasional (29-5%) HP:0001645
26 arthritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001369
27 nephropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0000112
28 peripheral neuropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0009830
29 skin ulcer 60 33 occasional (7.5%) Occasional (29-5%) HP:0200042
30 glomerulopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100820
31 keratitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000491
32 blepharitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000498
33 hypoplasia of the thymus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000778
34 chest pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0100749
35 epistaxis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000421
36 conjunctivitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000509
37 meningitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001287
38 neutropenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001875
39 sepsis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100806
40 abnormality of the menstrual cycle 60 33 occasional (7.5%) Occasional (29-5%) HP:0000140
41 gingival bleeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0000225
42 eczema 60 33 occasional (7.5%) Occasional (29-5%) HP:0000964
43 urticaria 60 33 occasional (7.5%) Occasional (29-5%) HP:0001025
44 intracranial hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0002170
45 acute leukemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002488
46 vasculitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002633
47 lymphoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0002665
48 chronic leukemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0005558
49 recurrent intrapulmonary hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0006535
50 abnormal platelet function 60 33 occasional (7.5%) Occasional (29-5%) HP:0011869

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Kidneys:
nephropathy

Head And Neck Head:
sinusitis

Skin Nails Hair Skin:
purpura
eczema
petechiae

Head And Neck Ears:
otitis media

Neurologic Central Nervous System:
meningitis

Respiratory Lung:
pneumonia

Head And Neck Mouth:
oral bleeding

Hematology:
hemolytic anemia
thrombocytopenia
iron deficiency anemia
small platelets size
small and large vessel vasculitis
more
Immunology:
lymphopenia
moderately depressed antibody response to polysaccharide antigens
abnormal delayed hypersensitivity skin test
absent microvilli on the surface of peripheral blood lymphocytes

Abdomen Gastrointestinal:
diarrhea
hematemesis
melena
inflammatory bowel disease

Head And Neck Nose:
epistaxis

Laboratory Abnormalities:
prolonged bleeding time
increased ige levels
reduced igm levels
normal igg levels
increased iga levels
more
Respiratory Airways:
upper respiratory tract infections
lower respiratory tract infections

Clinical features from OMIM:

301000

UMLS symptoms related to Wiskott-Aldrich Syndrome:


diarrhea, petechiae of skin

GenomeRNAi Phenotypes related to Wiskott-Aldrich Syndrome according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 NCK1 RAC1 RHOD WASF1 WASL
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.1 BTK CDC42 FYN NCK1 RAC1 WASF3

MGI Mouse Phenotypes related to Wiskott-Aldrich Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.32 BTK FYN PSTPIP1 RAC1 SPN SRC

Drugs & Therapeutics for Wiskott-Aldrich Syndrome

Drugs for Wiskott-Aldrich Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 439)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
4
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
5
Rutin Approved, Experimental, Investigational Phase 4,Phase 2 153-18-4 5280805
6
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
7
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
8
Indian frankincense Approved, Experimental, Investigational Phase 4
9
Ranibizumab Approved Phase 4,Phase 3 347396-82-1 459903
10
Everolimus Approved Phase 4,Phase 3 159351-69-6 6442177 70789204
11
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
14
Diltiazem Approved, Investigational Phase 4,Phase 3 42399-41-7 39186
15
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
16
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
17
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
18
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
19
Amlodipine Approved Phase 4 88150-42-9 2162
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
23
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
24
Sevelamer Approved Phase 4 52757-95-6
25
Calcium acetate Approved, Investigational Phase 4 62-54-4
26
Primaquine Approved Phase 4 90-34-6 4908
27
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
28
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
29
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
30
Budesonide Approved Phase 4 51333-22-3 63006 5281004
31
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
32
Glimepiride Approved Phase 4 93479-97-1 3476
33
Nicotine Approved Phase 4 54-11-5 942 89594
34
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
35
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
36
Carbidopa Approved Phase 4 28860-95-9 34359
37
Levodopa Approved Phase 4 59-92-7 6047
38
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
39
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
40
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Calcium Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1 7440-70-2 271
43 Garlic Approved, Nutraceutical Phase 4
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
45
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
46
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
47
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
48
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
49
Adefovir Investigational Phase 4 106941-25-7
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 206)
# Name Status NCT ID Phase Drugs
1 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
2 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
3 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects Completed NCT00634569 Phase 4
4 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
5 Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program Completed NCT01271218 Phase 4
6 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
7 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients Completed NCT00121810 Phase 4 mycophenolate mofetil [CellCept];Corticosteroids;Calcineurin inhibitors;Sirolimus
8 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin Completed NCT01422382 Phase 4 Pitavastatin (NK-104);Diltiazem (Cardizem LA) 240 mg QD
9 Postpartum Women's Dexmedetomidine Sedation Completed NCT02111421 Phase 4 Dexmedetomidine 01;Dexmetomidine 02
10 ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria Completed NCT01375322 Phase 4 Amlodipine+Benazepril;Valsartan+Hydrochlorothiazide
11 Effect of Aged Garlic Extract on Atherosclerosis Completed NCT01534910 Phase 4 aged garlic extract;placebo
12 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
13 The Influence of Age on Dexmedetomidine Pharmacodynamic Completed NCT02099253 Phase 4 Dexmedetomidine 01;Dexmedetomidine 02
14 Duloxetine Treatment in Elderly With Dysthymia Completed NCT01852383 Phase 4 Duloxetine
15 Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01135615 Phase 4 Sevelamer;calcium acetate
16 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
17 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed NCT00347009 Phase 4 adefovir dipivoxil
18 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule Completed NCT00291876 Phase 4
19 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
20 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
21 Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed NCT00993187 Phase 4 Sitagliptin/Metformin FDC;Comparator: Glimepiride;Matching placebo to Sitagliptin/Metformin FDC;Matching placebo to glimepiride
22 Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases Completed NCT01392014 Phase 4 dihydroartemisinin-piperaquine;dihydroartemisinin-piperaquine + primaquine
23 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
24 Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment Completed NCT00749463 Phase 4 Nicotine Gum;Nicotine Patch
25 Determination of Sufentanil in Breast Milk of Puerpera Completed NCT03764202 Phase 4
26 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Completed NCT00141518 Phase 4 Levodopa-carbidopa intestinal gel (LCIG)
27 Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center Completed NCT01944462 Phase 4
28 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
29 On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist Recruiting NCT02731794 Phase 4
30 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
31 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
32 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
33 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
34 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults Completed NCT01196975 Phase 3
35 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed NCT00312572 Phase 3 Buprenorphine transdermal patch
36 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura Completed NCT01071954 Phase 3
37 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
38 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Completed NCT00866775 Phase 3 Eslicarbazepine acetate;Eslicarbazepine acetate
39 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Completed NCT01091662 Phase 3 Eslicarbazepine acetate 1600 mg;Eslicarbazepine acetate 1200 mg
40 Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis Completed NCT01744782 Phase 3 RP103
41 Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children Completed NCT01196988 Phase 3
42 Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Completed NCT01652872 Phase 3
43 Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO) Completed NCT00803634 Phase 3 Clevidipine;Standard of Care IV antihypertensive
44 Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) Completed NCT01204671 Phase 3
45 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) Completed NCT01020487 Phase 3 Paricalcitol;Placebo
46 Silicone Gel in the Treatment of Cleft Lip Scars Completed NCT03314090 Phase 3 Silicone Gels
47 A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin Completed NCT00734474 Phase 2, Phase 3 LY2189265;Sitagliptin;Placebo solution;Placebo tablet;Metformin
48 Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes Completed NCT00116831 Phase 3 Glipizide;rosiglitazone maleate
49 Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection Completed NCT01069900 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Ertapenem;Amoxicillin/Clavulanate;Moxifloxacin placebo;Ertapenem placebo;Amoxicillin/Clavulanate placebo
50 Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys. Completed NCT03286517 Phase 3

Search NIH Clinical Center for Wiskott-Aldrich Syndrome

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Wiskott-Aldrich Syndrome cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: wiskott-aldrich syndrome

Genetic Tests for Wiskott-Aldrich Syndrome

Genetic tests related to Wiskott-Aldrich Syndrome:

# Genetic test Affiliating Genes
1 Wiskott-Aldrich Syndrome 30 WAS

Anatomical Context for Wiskott-Aldrich Syndrome

MalaCards organs/tissues related to Wiskott-Aldrich Syndrome:

42
Bone, Bone Marrow, Skin, T Cells, B Cells, Kidney, Eye

Publications for Wiskott-Aldrich Syndrome

Articles related to Wiskott-Aldrich Syndrome:

(show top 50) (show all 884)
# Title Authors Year
1
Yes-associated protein promotes cell migration via activating Wiskott-Aldrich syndrome protein family member 1 in oral squamous cell carcinoma. ( 30697796 )
2019
2
Monoclonal Gammopathy of Unclear Significance in a Child with Wiskott-Aldrich Syndrome: a Rare Occurrence. ( 30607662 )
2019
3
CRISPR/Cas9-mediated deletion of the Wiskott-Aldrich syndrome locus causes actin cytoskeleton disorganization in murine erythroleukemia cells. ( 30671311 )
2019
4
Lymphoproliferative Disease in Wiskott-Aldrich Syndrome. Analysis of the French Registry of Primary Immunodeficiencies. ( 30796981 )
2019
5
How I manage patients with Wiskott Aldrich syndrome. ( 30864154 )
2019
6
Autoimmune thyroiditis following HLA-matched sibling hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome. ( 29761856 )
2018
7
Discovering the Cause of Wiskott-Aldrich Syndrome and Laying the Foundation for Understanding Immune Cell Structuring. ( 29784762 )
2018
8
Autonomous role of Wiskott-Aldrich Syndrome platelet deficiency in inducing autoimmunity and inflammation. ( 29421274 )
2018
9
Get Outta Here! Addition of Mobilizing Agents to Conditioning Regimen Improves Donor Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Wiskott-Aldrich Syndrome. ( 29753160 )
2018
10
Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. ( 29316027 )
2018
11
Pillars Article: Isolation of a Novel Gene Mutated in Wiskott-Aldrich Syndrome. <i>Cell</i>. 1994. 78: 635-644. ( 29784763 )
2018
12
Unrelated umbilical cord stem cell transplantation in an eleven-month-old male infant with Wiskott-Aldrich syndrome. ( 29413229 )
2018
13
Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome. ( 29745014 )
2018
14
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. ( 29196934 )
2018
15
Neutrophils drive type-I interferon production and autoantibodies in Wiskott-Aldrich syndrome. ( 29447842 )
2018
16
Screening for Wiskott-Aldrich syndrome by flow cytometry. ( 29729304 )
2018
17
Neuropsychological Profile of a Girl with Wiskott-Aldrich Syndrome. ( 29561314 )
2018
18
Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection. ( 29348920 )
2018
19
Identification of Wiskott-Aldrich syndrome protein (WASP) binding sites on the branched actin filament nucleator Arp2/3 complex. ( 29386393 )
2018
20
MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like. ( 29621773 )
2018
21
A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRI+I^<sup>+</sup> and CD19<sup>+</sup> Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. ( 29550630 )
2018
22
Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. ( 29086100 )
2018
23
The Wiskott-Aldrich Syndrome Protein Contributes to the Assembly of the LFA-1 Nanocluster Belt at the Lytic Synapse. ( 29386139 )
2018
24
A novel splice site mutation in WAS gene in patient with Wiskott-Aldrich syndrome and chronic colitis: a case report. ( 30029636 )
2018
25
A Novel Mutation In A Child With Atypical Wiskott-Aldrich Syndrome Complicated by Cytomegalovirus Infection. ( 29983408 )
2018
26
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. ( 30510251 )
2018
27
Bleeding and splenectomy in Wiskott-Aldrich syndrome: A single-centre experience. ( 30048768 )
2018
28
One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. ( 30055182 )
2018
29
Surgical Resection Of Thoracic Aortic Aneurysms In Wiskott-Aldrich Syndrome. ( 30084784 )
2018
30
Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53± murine model. ( 30393584 )
2018
31
Descending aortic aneurysm in Wiskott-Aldrich syndrome: options for repair. ( 29022827 )
2017
32
Comparison of ZFNs versus CRISPR specific nucleases for genome edition of the Wiskott-Aldrich Syndrome locus. ( 28922955 )
2017
33
Un-manipulated Haploidentical Transplant in Wiskott-Aldrich Syndrome. ( 28474594 )
2017
34
Intermittent low platelet counts hampering diagnosis of X-linked thrombocytopenia in children: report of two unrelated cases and a novel mutation in the gene coding for the Wiskott-Aldrich syndrome protein. ( 28641574 )
2017
35
Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector. ( 28344987 )
2017
36
In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells. ( 28512459 )
2017
37
Nuclear Wiskott-Aldrich syndrome protein co-regulates T cell factor 1-mediated transcription in T cells. ( 29078804 )
2017
38
Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich syndrome. ( 29214738 )
2017
39
Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome. ( 28232030 )
2017
40
Wiskott-Aldrich syndrome protein: Emerging mechanisms in immunity. ( 28805251 )
2017
41
R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome. ( 29248492 )
2017
42
Successful Reduced Intensity Allogeneic Transplant With Full Donor Chimerism and Good Quality of Life in Adolescent Patient With Wiskott-Aldrich Syndrome. ( 28538502 )
2017
43
Low T Cell Numbers Resembling T-B+ SCID in a Patient with Wiskott-Aldrich Syndrome and the Outcome of Two Hematopoietic Stem Cell Transplantations. ( 27900584 )
2017
44
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. ( 29196075 )
2017
45
Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome. ( 28287640 )
2017
46
Abnormal distribution of distinct lymphocyte subsets in children with Wiskott-Aldrich syndrome. ( 28535968 )
2017
47
A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. ( 28255019 )
2017
48
Wiskott-Aldrich Syndrome Misdiagnosed as Immune Thrombocytopenic Purpura: A Case Report. ( 28859046 )
2017
49
Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene. ( 29358862 )
2017
50
50 Years Ago in The Journal of Pediatrics: Wiskott-Aldrich Syndrome: Clinical, Immunologic, and Pathologic Observations. ( 28129868 )
2017

Variations for Wiskott-Aldrich Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Wiskott-Aldrich Syndrome:

76 (show all 19)
# Symbol AA change Variation ID SNP ID
1 WAS p.Glu31Lys VAR_005825
2 WAS p.Ser82Pro VAR_005829 rs132630272
3 WAS p.Arg86His VAR_005830 rs132630268
4 WAS p.Arg86Leu VAR_005831 rs132630268
5 WAS p.Arg86Cys VAR_005832
6 WAS p.Trp97Cys VAR_005833
7 WAS p.Glu131Lys VAR_005834 rs146220228
8 WAS p.Glu133Lys VAR_005835
9 WAS p.Gly187Cys VAR_005836
10 WAS p.Lys476Glu VAR_005838
11 WAS p.Cys43Trp VAR_008105
12 WAS p.Thr45Met VAR_008106 rs132630273
13 WAS p.Cys73Arg VAR_008107
14 WAS p.Phe84Leu VAR_008109
15 WAS p.Gly89Asp VAR_008110 rs139857045
16 WAS p.Gln52His VAR_012710
17 WAS p.Gly70Trp VAR_012711
18 WAS p.Pro58Leu VAR_022806
19 WAS p.Ala134Thr VAR_022807

ClinVar genetic disease variations for Wiskott-Aldrich Syndrome:

6 (show top 50) (show all 90)
# Gene Variation Type Significance SNP ID Assembly Location
1 WAS WAS, 1-BP DEL, 211T deletion Pathogenic
2 WAS NM_000377.2(WAS): c.257G> T (p.Arg86Leu) single nucleotide variant Pathogenic rs132630268 GRCh37 Chromosome X, 48542796: 48542796
3 WAS NM_000377.2(WAS): c.257G> T (p.Arg86Leu) single nucleotide variant Pathogenic rs132630268 GRCh38 Chromosome X, 48684407: 48684407
4 WAS NM_000377.2(WAS): c.257G> A (p.Arg86His) single nucleotide variant Pathogenic rs132630268 GRCh37 Chromosome X, 48542796: 48542796
5 WAS NM_000377.2(WAS): c.257G> A (p.Arg86His) single nucleotide variant Pathogenic rs132630268 GRCh38 Chromosome X, 48684407: 48684407
6 WAS NM_000377.2(WAS): c.100C> T (p.Arg34Ter) single nucleotide variant Pathogenic rs132630271 GRCh37 Chromosome X, 48542342: 48542342
7 WAS NM_000377.2(WAS): c.100C> T (p.Arg34Ter) single nucleotide variant Pathogenic rs132630271 GRCh38 Chromosome X, 48683953: 48683953
8 WAS NM_000377.2(WAS): c.1A> T (p.Met1Leu) single nucleotide variant Pathogenic rs587776742 GRCh37 Chromosome X, 48542243: 48542243
9 WAS NM_000377.2(WAS): c.1A> T (p.Met1Leu) single nucleotide variant Pathogenic rs587776742 GRCh38 Chromosome X, 48683854: 48683854
10 WAS NM_000377.2(WAS): c.395_400dupACGAGG (p.Glu133_Ala134insAspGlu) duplication Pathogenic rs587776743 GRCh37 Chromosome X, 48544157: 48544162
11 WAS NM_000377.2(WAS): c.395_400dupACGAGG (p.Glu133_Ala134insAspGlu) duplication Pathogenic rs587776743 GRCh38 Chromosome X, 48685768: 48685773
12 WAS NM_000377.2(WAS): c.1097delG (p.Gly366Alafs) deletion Pathogenic rs587776744 GRCh37 Chromosome X, 48547214: 48547214
13 WAS NM_000377.2(WAS): c.1097delG (p.Gly366Alafs) deletion Pathogenic rs587776744 GRCh38 Chromosome X, 48688825: 48688825
14 WAS WAS, 15,800-BP DEL deletion Pathogenic
15 WAS WAS, IVS6DS, G-A, +5 single nucleotide variant Pathogenic
16 WAS WAS, IVS6AS, G-A, -1 single nucleotide variant Pathogenic
17 WAS WAS, IVS6DS, T-G, +2 single nucleotide variant Pathogenic
18 WAS NM_000377.2(WAS): c.11delG (p.Gly4Alafs) deletion Pathogenic rs587776745 GRCh37 Chromosome X, 48542253: 48542253
19 WAS NM_000377.2(WAS): c.11delG (p.Gly4Alafs) deletion Pathogenic rs587776745 GRCh38 Chromosome X, 48683864: 48683864
20 WAS WAS, 2-BP DEL, 73AC deletion Pathogenic
21 WAS WAS, 1-BP DEL, 758A deletion Pathogenic
22 WAS WAS, 1-BP DEL, CODON 241, C deletion Pathogenic
23 WAS NM_000377.2(WAS): c.37C> T (p.Arg13Ter) single nucleotide variant Pathogenic rs193922415 GRCh38 Chromosome X, 48683890: 48683890
24 WAS NM_000377.2(WAS): c.310C> T (p.Gln104Ter) single nucleotide variant Likely pathogenic rs193922414 GRCh37 Chromosome X, 48543972: 48543972
25 WAS NM_000377.2(WAS): c.310C> T (p.Gln104Ter) single nucleotide variant Likely pathogenic rs193922414 GRCh38 Chromosome X, 48685583: 48685583
26 WAS NM_000377.2(WAS): c.37C> T (p.Arg13Ter) single nucleotide variant Pathogenic rs193922415 GRCh37 Chromosome X, 48542279: 48542279
27 WAS NM_000377.2(WAS): c.1197_1205delACCGCCACC (p.Pro402_Pro404del) deletion Uncertain significance rs193922412 GRCh37 Chromosome X, 48547314: 48547322
28 WAS NM_000377.2(WAS): c.1197_1205delACCGCCACC (p.Pro402_Pro404del) deletion Uncertain significance rs193922412 GRCh38 Chromosome X, 48688925: 48688933
29 WAS NM_000377.2(WAS): c.273+10_273+11dupCC duplication Benign/Likely benign rs58371799 GRCh37 Chromosome X, 48542822: 48542823
30 WAS NM_000377.2(WAS): c.273+10_273+11dupCC duplication Benign/Likely benign rs58371799 GRCh38 Chromosome X, 48684433: 48684434
31 WAS NM_000377.2(WAS): c.538C> A (p.His180Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs145040665 GRCh37 Chromosome X, 48544502: 48544502
32 WAS NM_000377.2(WAS): c.538C> A (p.His180Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs145040665 GRCh38 Chromosome X, 48686113: 48686113
33 WAS NM_000377.2(WAS): c.763dupC (p.Gln255Profs) duplication Likely pathogenic rs193922416 GRCh37 Chromosome X, 48546471: 48546471
34 WAS NM_000377.2(WAS): c.763dupC (p.Gln255Profs) duplication Likely pathogenic rs193922416 GRCh38 Chromosome X, 48688082: 48688082
35 WAS NM_000377.2(WAS): c.995T> C (p.Val332Ala) single nucleotide variant Benign/Likely benign rs2737799 GRCh37 Chromosome X, 48547112: 48547112
36 WAS NM_000377.2(WAS): c.995T> C (p.Val332Ala) single nucleotide variant Benign/Likely benign rs2737799 GRCh38 Chromosome X, 48688723: 48688723
37 WAS NM_000377.2(WAS): c.1378C> T (p.Pro460Ser) single nucleotide variant Benign/Likely benign rs143885622 GRCh37 Chromosome X, 48547748: 48547748
38 WAS NM_000377.2(WAS): c.1378C> T (p.Pro460Ser) single nucleotide variant Benign/Likely benign rs143885622 GRCh38 Chromosome X, 48689359: 48689359
39 WAS NM_000377.2(WAS): c.391G> A (p.Glu131Lys) single nucleotide variant Benign/Likely benign rs146220228 GRCh37 Chromosome X, 48544153: 48544153
40 WAS NM_000377.2(WAS): c.391G> A (p.Glu131Lys) single nucleotide variant Benign/Likely benign rs146220228 GRCh38 Chromosome X, 48685764: 48685764
41 WAS NM_000377.2(WAS): c.273+11dupC duplication Benign/Likely benign rs58371799 GRCh37 Chromosome X, 48542823: 48542823
42 WAS NM_000377.2(WAS): c.273+11dupC duplication Benign/Likely benign rs58371799 GRCh38 Chromosome X, 48684434: 48684434
43 WAS NM_000377.2(WAS): c.873C> T (p.Tyr291=) single nucleotide variant Benign/Likely benign rs149123892 GRCh37 Chromosome X, 48546784: 48546784
44 WAS NM_000377.2(WAS): c.873C> T (p.Tyr291=) single nucleotide variant Benign/Likely benign rs149123892 GRCh38 Chromosome X, 48688395: 48688395
45 WAS NM_000377.2(WAS): c.777+1G> A single nucleotide variant Pathogenic rs1057517845 GRCh37 Chromosome X, 48546486: 48546486
46 WAS NM_000377.2(WAS): c.777+1G> A single nucleotide variant Pathogenic rs1057517845 GRCh38 Chromosome X, 48688097: 48688097
47 WAS NM_000377.2(WAS): c.90C> T (p.His30=) single nucleotide variant Benign rs148800063 GRCh38 Chromosome X, 48683943: 48683943
48 WAS NM_000377.2(WAS): c.90C> T (p.His30=) single nucleotide variant Benign rs148800063 GRCh37 Chromosome X, 48542332: 48542332
49 WAS NM_000377.2(WAS): c.852delC (p.Glu285Argfs) deletion Likely pathogenic rs1557007035 GRCh37 Chromosome X, 48546763: 48546763
50 WAS NM_000377.2(WAS): c.852delC (p.Glu285Argfs) deletion Likely pathogenic rs1557007035 GRCh38 Chromosome X, 48688374: 48688374

Expression for Wiskott-Aldrich Syndrome

Search GEO for disease gene expression data for Wiskott-Aldrich Syndrome.

Pathways for Wiskott-Aldrich Syndrome

Pathways related to Wiskott-Aldrich Syndrome according to KEGG:

38
# Name Kegg Source Accession
1 Endocytosis hsa04144
2 Regulation of actin cytoskeleton hsa04810

Pathways related to Wiskott-Aldrich Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 ACTR2 BTK CDC42 FYN NCK1 NCKIPSD
2
Show member pathways
14.08 ACTR2 BTK CDC42 FYN NCK1 NCKIPSD
3
Show member pathways
13.93 ACTR2 BTK CDC42 FYN RAC1 RHOD
4
Show member pathways
13.8 ACTR2 BTK CDC42 FYN NCK1 RAC1
5
Show member pathways
13.5 BTK CDC42 FYN NCK1 RAC1 SRC
6
Show member pathways
13.48 ACTR2 BTK CDC42 FYN RAC1 SRC
7
Show member pathways
13.38 ACTR2 BTK CDC42 FYN RAC1 RHOD
8
Show member pathways
13.28 BTK CDC42 FYN NCK1 RAC1 RHOD
9
Show member pathways
13.13 BTK CDC42 FYN RAC1 RHOD SRC
10
Show member pathways
13.08 ACTR2 CDC42 RAC1 SRC WAS WASF1
11
Show member pathways
13.04 ACTR2 CDC42 NCK1 RAC1 RHOD SRC
12
Show member pathways
13.01 ACTR2 BTK CDC42 FYN NCK1 RAC1
13
Show member pathways
13 ACTR2 CDC42 RAC1 RHOD SRC WAS
14
Show member pathways
12.96 CDC42 RAC1 RHOD SRC WAS WASL
15
Show member pathways
12.89 ACTR2 BTK CDC42 NCK1 NCKIPSD RAC1
16
Show member pathways
12.88 CDC42 FYN RAC1 SRC WASF1
17
Show member pathways
12.78 CDC42 NCK1 RAC1 SRC WASL
18
Show member pathways
12.77 FYN NCK1 RAC1 SRC WASL
19
Show member pathways
12.75 ACTR2 CDC42 RAC1 SRC WAS WASF1
20 12.75 CDC42 RAC1 SRC WAS WASF1 WASF2
21
Show member pathways
12.71 ACTR2 CDC42 FYN NCK1 RAC1 SRC
22
Show member pathways
12.69 BTK CDC42 FYN RAC1 SRC WIPF1
23
Show member pathways
12.63 CDC42 NCK1 RAC1 SRC
24
Show member pathways
12.63 ACTR2 CDC42 FYN NCK1 RAC1 SRC
25
Show member pathways
12.62 ACTR2 CDC42 FYN RAC1 WAS WIPF1
26 12.61 ACTR2 CDC42 NCK1 RAC1 WAS WASF2
27
Show member pathways
12.53 CDC42 FYN RAC1 SRC
28
Show member pathways
12.53 FYN RAC1 WAS WASF1 WASF2 WASF3
29
Show member pathways
12.52 CDC42 FYN NCK1 PSTPIP1 WAS
30 12.52 CDC42 SRC WAS WASHC1 WASL WIPF1
31
Show member pathways
12.49 CDC42 FYN NCK1 RAC1 SRC
32
Show member pathways
12.48 CDC42 FYN RAC1 SRC
33
Show member pathways
12.48 ACTR2 CDC42 RAC1 RHOD WASL
34
Show member pathways
12.48 ACTR2 CDC42 FYN RAC1 WAS
35
Show member pathways
12.47 BTK CDC42 FYN NCK1 RAC1
36
Show member pathways
12.45 BTK RAC1 RHOD SRC
37
Show member pathways
12.44 ACTR2 SNX9 TRIP10 WASL
38
Show member pathways
12.44 ACTR2 CDC42 FYN NCK1 RAC1 SRC
39
Show member pathways
12.41 ACTR2 RAC1 SRC WAS
40
Show member pathways